by James J. Leyden, MD, Department of Dermatology, University of Pennsylvania, Philadelphia, and the Skin Study Center, KGL, Inc., Broomall, Pennsylvania; Norman Preston, PhD; Galderma Laboratories, L.P., Fort Worth, Texas; Cris Osborn, PhD; Galderma Laboratories, L.P.; Ronald W. Gottschalk, MD, Galderma Laboratories, L.P.

Disclosure: Dr. Leyden is a consultant for Galderma Laboratories, L.P. Drs. Preston, Osborn, and Gottschalk are employees of Galderma Laboratories, L.P. This study was funded by Galderma Laboratories, L.P. Read the rest of this article »

Message from the Section Editor
As the Section Editor of the “Aesthetic Update” section of The Journal of Clinical and Aesthetic Dermatology (JCAD), it is my extreme privilege to introduce a new series of guest submissions. We have invited some of the leading experts in aesthetic dermatology to contribute to the Aesthtic Update in 2011, and each one of them has been tasked with writing a commentary based on their experiences in a specific field or writing a review of a topic for which they feel passionate. I hope you find this Special Section interesting, stimulating, and provocative—and I welcome your comments on these cosmetic and aesthetic topics. Read the rest of this article »

Leon H. Kircik, MD, Indiana University School of Medicine, Indianapolis, Indiana; Mount Sinai Medical Center, New York, New York; DermResearch, PLLC, Louisville, Kentucky Read the rest of this article »

James Q. Del Rosso, DO, Dermatology Residency Program Director, Valley Hospital Medical Center, Las Vegas, Nevada

Disclosure: Dr. Del Rosso is a consultant, speaker, and/or researcher for Allergan, Coria, Galderma, Graceway, Intendis, Leo Pharma, Medicis, Onset Therapeutics, Ortho Dermatology, PharmaDerm, Promius, Quinnova, Ranbaxy, SkinMedica, Stiefel, Triax, Unilever, and Warner Chilcott. Read the rest of this article »

Joshua A. Zeichner, MD; Rita V. Patel, MD; Miriam B. Birge, MD, both from Mount Sinai Medical Center, New York, New York

Disclosure: The authors report no relevant conflicts of interest.

Abstract
Basal cell carcinoma is the most common form of nonmelanoma skin cancer in the United States. Treatment modalities include both surgical, medical, or combination therapy. In the following case, the authors report the successful treatment of a basal cell carcinoma on the nose with curettage followed by topical imiquimod 3.75% cream.
(J Clin Aesthet Dermatol. 2011;4(5):39–43.) Read the rest of this article »

Richard G. Fried, MD, PhD

Dr. Fried is in private practice, Yardley Dermatology Associates, Yardley, Pennsylvania. Disclosure: Dr. Fried is a consultant or speaker for Allergan and Bioform Medical. Read the rest of this article »